Nucleai

Nucleai

Nucleai

Nucleai transforms immunotherapy treatment decisions and research by AI-powered Tumor Micro Environment (TME) modeling
Founded
2017
Raised
$11.5M
Follow us
Alexa global traffic share
Latest funding
$6,500,000
Venture capital (Series A) - 2020
Grove Ventures Vertex Ventures Debiopharm
$5,000,000
Seed fund - 2018
Grove Ventures Vertex Ventures Nir Kalkstein
Team Size
1–10
Employees
Location
Headquarters
neurons.AI

Israeli AI firm Nucleai, Sheba launch partnership for data collaboration

neurons.AI

Israeli AI firm Nucleai, Sheba launch partnership for data collaboration

neurons.AI

Nucleai and Debiopharm Launch Research Collaboration Utilizing Nucleai’s Ai-Powered …

$6,500,000 Venture capital (Series A)
Verdict

Nucleai raises $6.5m to advance predictive oncology platform